Literature DB >> 19047130

Targeting the stroma by T cells to limit tumor growth.

Bin Zhang1.   

Abstract

Solid tumors may modulate their environment and keep stromal cells in an immunosuppressive and tumor-promoting state. Recent findings indicate that targeting not only cancer cells but also nonmalignant stromal cells by T cells is required for the eradication of established tumor. Interestingly, a single adoptive transfer of effector T cells that recognize tumor antigen-loaded stromal cells, but not the cancer cells themselves, causes long-term inhibition of tumor growth associated with T cell-mediated killing of stromal CD11b+/Gr1+ myeloid cells. Therefore, targeting tumor stroma by T cells points to an important alternative approach to the effective control of tumor growth, particularly in the absence of direct targeting of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047130     DOI: 10.1158/0008-5472.CAN-08-2414

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.

Authors:  Giulia Grisendi; Rita Bussolari; Elena Veronesi; Serena Piccinno; Jorge S Burns; Giorgio De Santis; Pietro Loschi; Marco Pignatti; Fabrizio Di Benedetto; Roberto Ballarin; Carmela Di Gregorio; Valentina Guarneri; Lino Piccinini; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici
Journal:  Am J Cancer Res       Date:  2011-05-28       Impact factor: 6.166

Review 2.  Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?

Authors:  Tamas A Gonda; Andrea Varro; Timothy C Wang; Benjamin Tycko
Journal:  Semin Cell Dev Biol       Date:  2009-10-17       Impact factor: 7.727

3.  Tumor talk: understanding the conversation between the tumor and its microenvironment.

Authors:  Chery A Whipple
Journal:  Cancer Cell Microenviron       Date:  2015-04-26

4.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

5.  T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

Authors:  Philip D Greenberg; Sunil R Hingorani; Ingunn M Stromnes; Thomas M Schmitt; Ayaka Hulbert; J Scott Brockenbrough; Hieu Nguyen; Carlos Cuevas; Ashley M Dotson; Xiaoxia Tan; Jennifer L Hotes
Journal:  Cancer Cell       Date:  2015-10-29       Impact factor: 31.743

6.  Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.

Authors:  Beatriz Perez-Villamil; Alejandro Romera-Lopez; Susana Hernandez-Prieto; Guillermo Lopez-Campos; Antonio Calles; Jose-Antonio Lopez-Asenjo; Julian Sanz-Ortega; Cristina Fernandez-Perez; Javier Sastre; Rosario Alfonso; Trinidad Caldes; Fernando Martin-Sanchez; Eduardo Diaz-Rubio
Journal:  BMC Cancer       Date:  2012-06-19       Impact factor: 4.430

7.  Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients.

Authors:  Giuseppe Roscilli; Manuela Cappelletti; Claudia De Vitis; Gennaro Ciliberto; Arianna Di Napoli; Luigi Ruco; Rita Mancini; Luigi Aurisicchio
Journal:  J Transl Med       Date:  2014-02-24       Impact factor: 5.531

Review 8.  The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches.

Authors:  Narges Zafari; Fatemeh Khosravi; Zahra Rezaee; Sahar Esfandyari; Mohamad Bahiraei; Afshin Bahramy; Gordon A Ferns; Amir Avan
Journal:  J Clin Lab Anal       Date:  2022-07-08       Impact factor: 3.124

Review 9.  Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.

Authors:  Zhi Zhu; A J Robert McGray; Weijian Jiang; Binfeng Lu; Pawel Kalinski; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2022-10-12       Impact factor: 41.444

10.  Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.

Authors:  Ruben Rene Gonzalez; Amber Watters; Yanbo Xu; Udai P Singh; David R Mann; Bo R Rueda; Manuel L Penichet
Journal:  Breast Cancer Res       Date:  2009-06-16       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.